SOURCE: CancerVax

August 31, 2005 16:30 ET

CancerVax to Webcast Corporate Presentation at Thomas Weisel Healthcare Tailwinds 2005 Conference

CARLSBAD, CA -- (MARKET WIRE) -- August 31, 2005 -- CancerVax Corporation (NASDAQ: CNVX) announced today that President and CEO David F. Hale will present a corporate overview on Thursday, September 8, 2005 at 8:00 a.m. EDT during the Thomas Weisel Healthcare Tailwinds 2005 Conference. Mr. Hale's presentation will provide an overview of the Company's pipeline of biological products for the treatment and control of cancer, including Canvaxin™, an investigational specific active immunotherapy product candidate in a Phase 3 clinical trial for the treatment of patients with Stage III melanoma, a deadly form of skin cancer.

A live recording of CancerVax's presentation will be available at http://ir.cancervax.com. To access the presentation, click on the link entitled "Event Schedule" on the left side of the screen. The webcast will be available for 30 days and then archived.

About CancerVax Corporation (www.cancervax.com)

CancerVax Corporation is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. The Company's lead product candidate, Canvaxin™, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines. Canvaxin™ is currently being studied in an international Phase 3 clinical trial for the treatment of patients with Stage III melanoma. In December 2004, CancerVax announced an exclusive worldwide collaboration with Serono Technologies, S.A., a Swiss corporation, for the development and commercialization of Canvaxin. CancerVax also has a pipeline of product candidates and technologies that are being developed for the potential treatment of cancer. These include: SAI-EGF, an investigational product candidate that targets the epidermal growth factor (EGF) receptor signaling pathway, which is currently being evaluated in Phase 2 clinical trials for the treatment of patients with non-small-cell lung cancer; and D93, CancerVax's lead anti-angiogenic humanized monoclonal antibody. CancerVax's corporate headquarters and research and development facility is located in Carlsbad, Calif., and its biologics manufacturing facility is located in the Los Angeles area.

Forward-Looking Statements

CancerVax cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. For example, statements about the Company's financial condition, the possible or assumed future results of operations and financial projections, the timing or possible results of the interim and final analyses of the Phase 3 clinical trial of Canvaxin in patients with Stage III melanoma, the timing of the initiation of other clinical trials of Canvaxin or any of CancerVax's other product candidates, and plans and objectives of management, are all forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by CancerVax that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in CancerVax's business including, without limitation, statements about: difficulties or delays in researching, developing, testing, obtaining regulatory approval, producing and marketing its technologies and product candidates; the risk that the collaboration agreement may be terminated by Serono in certain instances; its ability to obtain additional financing to support its operations, which could adversely affect its ability to develop or commercialize its product candidates and its ability to continue to operate as a going concern; and other risks detailed in CancerVax's Securities and Exchange Commission filings, including CancerVax's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2005. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and CancerVax undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

CancerVax® is a registered trademark of CancerVax Corporation.

Canvaxin™ is a trademark of CancerVax Corporation.

Contact Information

  • Contacts:
    William R. LaRue
    CancerVax Corporation
    SVP, CFO
    760-494-4200

    Trista Morrison
    Atkins + Associates
    Media & Investor Relations
    858-527-3490